3. DESCRIPTION OF THE MEASURE › 3.2. Exemption from the manufacturer's rebate on pharmaceutical products under German law, Decision_act (EU) 2015/1300

In forcesince 27 Mar 2015
(21)

According the information sheet published by BAFA, the decisive elements taken into account by it for establishing whether an exemption is to be granted are the following:

(a)

Operating earnings before tax of the previous three business years;

(b)

A demonstration by the applicant for an exemption of the development of its earnings and liquidity during the previous three years on the basis of its key business indicators (e.g. its EBIT margin, return on equity, equity and debt ratio, liquidity and debt ratio) and an explanation of the effects of the price freeze on these indicators;

(c)

A demonstration by the applicant of the additional burden introduced on the business group/undertaking by the price freeze on the basis of a proof of the actual amount of the rebates already paid;

(d)

An assessment of the overall financial and economic situation of the applicant which takes, in addition to the revenue/profit situation, in particular also its assets and liquidity into account. To this end a retrospective cash flow statement as well as a prospective cash flow statement (financial pan), as well as a liquidity plan for the coming three years and a short-term financial plan for the coming 12 months have to be submitted by the applicant.